Answers are grounded in this paper and cite their sources.
Background. Hepatitis B (HBV) and Hepatitis C (HCV) present significant challenges for hemodialysis patients due to impaired immunity and frequent blood exposures. Advancements in antiviral therapies, infection control measures, and vaccination are critical for reducing their burden. Purpose of the review. To evaluate the epidemiology, management, and prevention of HBV and HCV in hemodialysis patients. The review synthesized current research on transmission, infection control, antiviral therapies, and vaccination strategies, emphasizing their role in improving patient outcomes. Materials and methods. A systematic review of PubMed, Google Scholar, and Cochrane Library (2000–2022) using keywords like «Hepatitis B,» «Hepatitis C,» «Hemodialysis,» «Infection Control,» and «Vaccination.» Conclusions: HBV and HCV remain critical concerns in hemodialysis settings. Advances in therapy, combined with preventive measures, are essential for better patient outcomes and infection control.
No takes yet. Share an insight, caveat, or question.
Yespotayeva et al. (2025) studied this question.
Synapse has enriched 9 related papers. Consider them for comparative context: